Titel
Accueil
Navigation principale
Contenu
Recherche
Aide
Fonte
Standard
Gras
Identifiant
Interrompre la session?
Une session sous le nom de
InternetUser
est en cours.
Souhaitez-vous vraiment vous déconnecter?
Interrompre la session?
Une session sous le nom de
InternetUser
est en cours.
Souhaitez-vous vraiment vous déconnecter?
Accueil
Plus de données
Partenaires
Aide
Mentions légales
D
F
E
La recherche est en cours.
Interrompre la recherche
Recherche de projets
Projet actuel
Projets récents
Graphiques
Identifiant
Titel
Titel
Unité de recherche
PCRD EU
Numéro de projet
99.0732
Titre du projet
ENDEVAN: European network on the development of artificial nucleases
Titre du projet anglais
ENDEVAN: European network on the development of artificial nucleases
Données de base
Textes
Participants
Titel
Textes relatifs à ce projet
Allemand
Français
Italien
Anglais
Mots-clé
-
-
-
Autre Numéro de projet
-
-
-
Programme de recherche
-
-
-
Description succincte
-
-
-
Autres indications
-
-
-
Partenaires et organisations internationales
-
-
-
Résumé des résultats (Abstract)
-
-
-
Références bases de données
-
-
-
Textes saisis
Catégorie
Texte
Mots-clé
(Anglais)
Oligonucleotides; nuclease mimicks; DNA analogues; RNA hydrolysis;
Education; Training; Scientific Research; Social Aspects
Autre Numéro de projet
(Anglais)
EU project number: RTN1-1999-00008
Programme de recherche
(Anglais)
EU-programme: 5. Frame Research Programme - 4.1.1 Research training networks
Description succincte
(Anglais)
See abstract
Autres indications
(Anglais)
Full name of research-institution/enterprise:
Universität Bern
Departement für Chemie und Biochemie
Partenaires et organisations internationales
(Anglais)
Coordinator: UCAM, Cambridge (UK)
Résumé des résultats (Abstract)
(Anglais)
This proposal is part of a long-term strategy aimed at developing drugs which act catalytically (thus as artificial enzymes) to interfere with the expression of specific genes. It is aimed at developing a class of artificial nuclease enzymes designed to interrupt the expression of specific genes using the antisense approach. Artificial nucleases are potentially valuable therapeutic agents, allowing in principle the regulation of the expression of a single gene. The general area of antisense therapy is of great topical interest: several antisense compounds have reached the final stages of clinical trials, and first of them has recently come on the market. The design of artificial enzymes to work in vitro major problems of molecular recognition: recognition of the substrate, which is the basis of substrate specificity an allow a specific substrate to be selected from a mixture in solution; a recognition of the transition state -the basis of efficient catalysis of the target reaction. We have specific proposals for the solution of both of these problems. The proposed Network brings together groups from six different EU countries who together offer a comprehensive range of complementary, relevant expertise. Three groups are expert in the synthesis of naturally occurring and modified nucleic acids, especially modified oligonucleotides stable to nucleases which are known to bind to DNA and RNA: two groups have very new systems which bind to DNA and RNA, and four groups offer intensive and wide-ranging expertise in the area of biocatalysis.
Références bases de données
(Anglais)
Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. +41 31 322 74 82
Swiss Project-Number: 99.0732
SEFRI
- Einsteinstrasse 2 - 3003 Berne -
Mentions légales